^
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Thyroid Gland Anaplastic Carcinoma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Anaplastic Carcinoma
CaT
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
cisplatin
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
docetaxel + doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
doxorubicin hydrochloride
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
paclitaxel
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
A2
RET mutation
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive
:
A2
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
carboplatin + paclitaxel
Sensitive
:
A2
RET fusion
Thyroid Gland Anaplastic Carcinoma
pralsetinib
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
AIC100
Sensitive
:
B
EGFR L858R
Thyroid Gland Anaplastic Carcinoma
erlotinib
Sensitive
:
C1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Resistant
:
C1
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive
:
C2
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
FORE-8394 + cobicistat
Sensitive
:
C3
PD-L1 overexpression
Thyroid Gland Anaplastic Carcinoma
pembrolizumab + lenvatinib
Sensitive
:
C3
TMB-H
Thyroid Gland Anaplastic Carcinoma
pembrolizumab + lenvatinib
Sensitive
:
C3
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + vemurafenib
Sensitive
:
C3
NF1 mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive
:
C3
KRAS mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive
:
C3
RAS mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive
:
C3
NF2 mutation
Thyroid Gland Anaplastic Carcinoma
atezolizumab + cobimetinib
Sensitive
:
C3
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF inhibitor
Sensitive
:
C3
NTRK3 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
C3
NTRK2 positive
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive
:
C3